ZYRTEC Drug Patent Profile

Which patents cover Zyrtec, and when can generic versions of Zyrtec launch?

Zyrtec is a drug marketed by J And J Consumer Inc and Kenvue Brands and is included in four NDAs.

The generic ingredient in ZYRTEC is cetirizine hydrochloride; pseudoephedrine hydrochloride. There are thirty-nine drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the cetirizine hydrochloride; pseudoephedrine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zyrtec

A generic version of ZYRTEC was approved as cetirizine hydrochloride; pseudoephedrine hydrochloride by IVAX SUB TEVA PHARMS on February 25^th, 2008.

Summary for ZYRTEC

US Patents:	0
Applicants:	2
NDAs:	4
Raw Ingredient (Bulk) Api Vendors:	109
Clinical Trials:	30
Patent Applications:	4,703
Drug Sales Revenues:	Drug sales revenues for ZYRTEC
What excipients (inactive ingredients) are in ZYRTEC?	ZYRTEC excipients list
DailyMed Link:	ZYRTEC at DailyMed

See drug sales revenues for ZYRTEC

Recent Clinical Trials for ZYRTEC

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Emory University	Phase 4
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division	Phase 1
Indiana University	Phase 4

See all ZYRTEC clinical trials

Paragraph IV (Patent) Challenges for ZYRTEC

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZYRTEC	Syrup	cetirizine hydrochloride	5 mg/5 mL	020346	1	2007-03-19

US Patents and Regulatory Information for ZYRTEC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
J And J Consumer Inc	ZYRTEC	cetirizine hydrochloride	SOLUTION;ORAL	020346-001	Sep 27, 1996		DISCN	Yes	No
Kenvue Brands	ZYRTEC-D 12 HOUR	cetirizine hydrochloride; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021150-002	Nov 9, 2007		OTC	Yes	Yes
Kenvue Brands	ZYRTEC ALLERGY	cetirizine hydrochloride	TABLET;ORAL	019835-004	Nov 16, 2007		OTC	Yes	Yes
Kenvue Brands	ZYRTEC ALLERGY	cetirizine hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	022578-001	Sep 3, 2010		OTC	Yes	Yes
Kenvue Brands	ZYRTEC ALLERGY	cetirizine hydrochloride	TABLET;ORAL	019835-003	Nov 16, 2007		OTC	Yes	No
Kenvue Brands	ZYRTEC HIVES	cetirizine hydrochloride	TABLET;ORAL	019835-006	Nov 16, 2007		DISCN	Yes	No

International Patents for ZYRTEC

See the table below for patents covering ZYRTEC around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	8140
Australia	544066
Australia	8023182
Bosnia and Herzegovina	97198
Bosnia and Herzegovina	97199
Canada	1199918	ACIDES 2-[4-(DIPHENYLMETHYL)-1-PIPERAZINYL] ACETIQUES ET LEURS AMIDES (2-[4-(DIPHENYLMETHYL)-1-PIPERAZINYL]-ACETIC ACIDS AND THEIR AMIDES)

Supplementary Protection Certificates for ZYRTEC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0058146	2001C/045	Belgium		PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103
0058146	SPC/GB01/052	United Kingdom		SPC/GB01/052:, EXPIRES: 20070205
0663828	C300085	Netherlands		PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103

Market Dynamics and Financial Trajectory for ZYRTEC

Last updated: March 13, 2026

What is the current market position of ZYRTEC?

ZYRTEC (cetirizine) is an antihistamine indicated for allergy relief, including hay fever, hives, and indoor and outdoor allergies. As of 2023, it remains one of the leading OTC antihistamines globally. Its market share within the OTC allergy segment approaches 35%, primarily in North America and Europe [[1]].

How is ZYRTEC's market evolving?

The global allergy medication market was valued at approximately $30 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4.5% through 2030 [[2]]. ZYRTEC benefits from the following trends:

• Increasing allergy prevalence, driven by pollution and climate changes.
• Rising demand for OTC medications as consumers prefer self-treatment.
• Continued expansion into emerging markets, where OTC sales are less regulated but expanding.

In 2022, ZYRTEC generated sales estimated at $1.8 billion, accounting for approximately 6% of the total global allergy medication market [[3]].

What are the competitive pressures impacting ZYRTEC?

Major competitors include Allegra (fexofenadine), Claritin (loratadine), and Nasacort (triamcinolone nasal spray). The key distinguishing factor is the safety profile and prescription versus OTC status:

• Allegra holds a 25% market share within OTC antihistamines.
• Claritin holds about 30%.
• Nasacort dominates nasal steroids, with about 15% market share.

Generic versions of cetirizine entered markets as early as 2010, eroding branded sales [[4]]. However, ZYRTEC retains its brand strength through:

• Strong consumer loyalty.
• OTC marketing campaigns.
• Pharmacist recommendation.

How do patent and regulatory factors influence ZYRTEC's trajectory?

ZYRTEC’s original patent expired in 2007; subsequent formulations have patents expired, allowing generics. The last significant patent protection was for specific formulations or delivery methods, which expired by 2012.

Regulatory decisions have affected OTC status. ZYRTEC is classified as OTC in several key markets; however, in some regions, prescription status persists for certain formulations or age groups, impacting revenues.

What is the revenue outlook for ZYRTEC over the next five years?

Projected sales growth is modest due to generic competition but supported by population growth and increasing allergy prevalence. The following assumptions underpin the forecast:

• Slight market share gains in emerging markets.
• Launch of new formulation variants (e.g., allergen-specific tablets).
• Price increases in select markets, averaging 2% annually.

Estimates project sales will reach approximately $2.0 billion by 2027, with a CAGR of roughly 1.5%. These figures consider generic erosion and evolving competitive landscape[[3]].

How do pricing strategies influence ZYRTEC’s performance?

Branded antihistamines like ZYRTEC command a premium over generics, with retail prices approximately 20-30% higher in the U.S. [[5]]. Price sensitivity varies across regions; higher-income markets sustain premium pricing.

Pharmaceutical companies are employing strategies such as bundling and targeted marketing to maintain revenue streams. OTC sales promotion in pharmacies and digital channels also contribute to sustained demand.

What are the potential risks impacting ZYRTEC’s financial trajectory?

• Erosion of brand loyalty due to aggressive generic competition.
• Regulatory changes restricting OTC access.
• Development of new allergy treatments or formulations that outperform existing options.
• Fluctuations in raw material prices, especially for cetirizine.

What are the key factors shaping long-term viability?

• Continued market growth driven by allergy prevalence.
• Ability to innovate formulations and delivery methods.
• Expansion into underserved markets.
• Maintaining regulatory approvals and competitive pricing.

Key Takeaways

ZYRTEC maintains a strong position in the OTC allergy space, with steady revenue growth driven by allergy prevalence and brand loyalty. Competition from generics remains a primary challenge, limiting exponential growth. Market expansion into emerging markets and formulation innovation provide avenues for continued relevance. Revenue projections indicate modest growth, influenced by price strategies and regional regulatory environments.

FAQs

1. Will ZYRTEC's revenue decline with generic competition?
Yes, generic erosion reduces brand sales, but ZYRTEC relies on brand loyalty, marketing, and regional positioning to mitigate decline.

2. Are there new formulations of ZYRTEC in development?
No widely announced new formulations; however, there are ongoing efforts in combination therapies and allergen-specific tablets.

3. How does ZYRTEC compare with competitors in safety profiles?
It has a well-established safety profile, comparable to other second-generation antihistamines like loratadine and fexofenadine.

4. Can regulatory changes impact ZYRTEC's OTC status?
Yes. Changes in regulations or safety concerns could lead to reclassification or restricted sales.

5. Which markets present the most growth opportunities for ZYRTEC?
Emerging markets in Asia and Latin America, owing to rising allergy rates and expanding OTC channels.

---

References

[1] MarketResearch.com. (2023). Global allergy medication market report.
[2] Grand View Research. (2022). Allergy Treatment Market Size, Share & Trends.
[3] Company financial reports. (2022). ZYRTEC revenue analysis.
[4] U.S. FDA. (2012). OTC drug approvals and patent information.
[5] IQVIA. (2023). Prescription and OTC drug pricing data.

DrugChatter Q&A for ZYRTEC

Do i need a doctor's approval to combine zyrtec and lipitor?
Zyrtec otc allergy medication seasonal performance sales revenue 2025 2026?
Zyrtec patent expiration date us?
Zyrtec patent expiration date?
Why is zyrtec so expensive?